{
  "id": 843394,
  "title": "Navamedic reports 2.2% revenue growth in second quarter",
  "url": "https://urgent.news/2026/08/14/navamedic-reports-2-2-revenue-growth-in-second-quarter",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-14T06:15:37.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/navamedic-reports-22-revenue-growth-in-second-quarter-93CH-4859793"
  },
  "original_language": "en",
  "account": "Navamedic ASA reported a modest 2.2% increase in revenue for the second quarter of 2026, reaching NOK 140.3 million. The Norway-based healthcare products company saw an improvement in its adjusted EBITDA margin, which rose to 11.3% from 7.4% in the same period last year. Gross margin for the quarter stood at 38.4%.\n\nThe company's Prescription Drugs business area drove growth in the quarter, including contributions from the Addiction portfolio acquired in July 2025. However, the Consumer Health segment experienced a decline in revenue due to heightened competition, particularly affecting the Modifast product. The EBITDA margin was negatively impacted by extraordinary costs related to a CEO change and inventory write-offs during the period.\n\nNavamedic anticipates stable revenue for 2026, similar to 2025 levels. The company expects improved gross margins for the year due to a more favorable product mix. Additionally, EBITDA is projected to improve compared to 2025.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}